



**Medical Solutions plc**  
**Presentation to Investors**  
**July 2007**



## Disclaimer

In the interest of providing Medical Solutions' shareholders and potential investors with information regarding the Company, including management's assessment of the Company's future plans and operations, certain statements and charts throughout this presentation are "forward-looking statements" and represent the Company's internal projections, expectations or beliefs concerning, among other things, future operating results and various components thereof or the Company's future economic performance.


The projections, estimates and beliefs contained in such forward looking statements necessarily involve known and unknown risks and uncertainties which may cause the Company's actual performance and financial results in future periods to differ materially from any estimates or projections. Nothing in this presentation should be construed as a profit forecast.




## About Medical Solutions

- Focused diagnostics and healthcare business, providing pathology, cytology and genomic services and products to the healthcare, pharmaceutical, biotechnology and research sectors
- State of the art reference laboratories in Nottingham and Cambridge
- Fully listed (listed 1999)
- Two core operating activities:
  - **Healthcare services**
    - diagnostic histopathology services
    - specialist reference laboratory testing and cancer diagnostic portfolios
    - distribution of SurePath™ liquid based cytology ('LBC') equipment and consumables
  - **Diagnostic services**
    - gene expression profiling
    - gene sequencing and genotyping
    - genomic products for gene research

# Group overview



# The Board



## Key events during 2007

- Acquisition of Geneservice Limited for £3.86m
- Appointed as exclusive UK distributor for OncotypeDX™ by Genomic Health, Inc.
- Acquisition of a 40% investment in Number One Health Limited
- Breast cancer diagnostic portfolio launched to private sector healthcare
- Wales trial for automated cervical cancer screening commenced
- Trials for ProExC™ cervical cancer diagnostic commenced
- Appointed as the exclusive UK commercial reference laboratory for CellSearch™ CTC enumeration
- Maintained CPA accreditation and GLP compliance; licensed by the Human Tissue Authority

## **Geneservice – benefits of the acquisition**

- **Profitable, expanding, cash generative business**
- **Complementary genomic services and products**
- **High end technology platforms and equipment**
- **Complementary customer base and expertise**
- **Consolidation of operations into Nottingham and cost savings**


## “One-stop shop”

- **Medical Solutions now provides a “one-stop shop” for diagnostic services from tissue pathology, through immunohistochemistry and in-situ hybridisation to genomic services including gene expression profiling and genotyping**
- **Pharma/biotech applications include:**
  - **molecular diagnostic analysis for pre and early-stage clinical drug development programmes**
  - **pharmacogenomics**
    - **patient metabolism of novel and existing drug therapies**
    - **disease associations and patient predisposition to disease**
    - **disease response to drug therapies**
- **Healthcare applications include:**
  - **diagnostic, prognostic and theranostic profiling**
  - **companion diagnostics**



## Current activities - Healthcare

- *Provision of expert pathology services to public and private healthcare, in a CPA accredited environment*
- **Histopathology services**
- **Established network of expert consultant pathologists**
- **Cytology services and products including SurePath™ LBC equipment**
- **Reference laboratory testing services for the diagnosis and treatment evaluation of cancer**
- **Portfolio of diagnostic tests aimed at the prognosis and therapy response for breast cancer patients; portfolio includes *oncotypeDX™*; further portfolios under development**
- **Number One Health provides private practice healthcare and route to market for services and products**



## Current services - Diagnostics


- *Provision of a range of expert services from histopathology to cutting edge molecular genetics to support development of therapeutics by pharma and biotech, all in a GLP compliant environment*
- **Regulatory studies involving for example immunohistochemistry, in situ hybridisation and antibody cross-reactivity**
- **Quantitative image analysis using sophisticated, fast image acquisition platform and proprietary software**
- **Fully consented tissue resource licensed by the Human Tissue Authority**
- **DNA sequencing, gene expression analysis and genotyping for disease association and therapy response**
- **Extensive libraries of DNA and RNA from human and other species**

## Growth strategy

- **Cross-selling opportunities arising from the Geneservice acquisition**
- **Organic growth of core competencies of histopathology, cytology, reference laboratory and genomic services**
- **Targeted acquisitions and investments to enhance our healthcare and diagnostic portfolio**

## Growth strategy – specific opportunities

- **Healthcare**
  - enhanced portfolio of diagnostic and theranostic tests aimed at clinicians and patients, initially for cancer
  - molecular diagnostic markers for cervical cancer
  - automated cervical cancer screening
  - non-tissue pathology
- **Diagnostics**
  - pharmacogenomics - stratification of patients and diseases for targeted therapies
  - exploitation of tissue bank
  - development of companion diagnostics in-house
  - migrate latest diagnostic developments into healthcare arena



## Key financials

- **Cash of £15.2 million at 31 December 2006**
- **Strong balance sheet with net current assets of £13.3 million at 31 December 2006 and debt of only £0.4 million**
- **Operating loss of £2.4 million in 2006, reduced by £1.0 million from 2005**
- **Revenue of £6.0 million in 2006, increased by 7% compared with 2005**
- **Improved gross margin to 40% in 2006 from 35% in 2005**
- **Administrative expenses reduced by £0.5 million in 2006**
- **Continued focus on cost control and cost reduction during 2007**